Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Many Faces of Myocarditis: Role of Cardiac MRI.

Radiology·2021

Same author

Normal and reference values for cardiovascular magnetic resonance-based pulse wave velocity in the middle-aged general population.

Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance·2021

Same author

Predicting Atrial Fibrillation from Automated Measurements of Left Atrial Volume Using Routine Chest CT Examination: Overlooked and Underrecognized Risk Factors.

Radiology. Cardiothoracic imaging·2021

Same author

Association Between Hepatic Triglyceride Content and Coagulation Factors: The Netherlands Epidemiology of Obesity Study.

Arteriosclerosis, thrombosis, and vascular biology·2020

Same author

Hypertensive Exposure Markers by MRI in Relation to Cerebral Small Vessel Disease and Cognitive Impairment.

JACC. Cardiovascular imaging·2020

Same author

Exploring the Interaction between Liver and Heart Disease.

Radiology·2020

Search research articles

Related Experiment Video

Updated: Jun 16, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Pioglitazone decreases plasma cholesteryl ester transfer protein mass, associated with a decrease in hepatic

Jacqueline T Jonker¹, Yanan Wang, Willeke de Haan

¹Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, the Netherlands. j.t.jonker@lumc.nl

|February 13, 2010

Summary

Pioglitazone effectively reduces liver fat and lowers cholesteryl ester transfer protein (CETP) mass in patients with type 2 diabetes. This leads to increased high-density lipoprotein (HDL) cholesterol levels, confirming findings in mouse models.

Related Experiment Videos

Last Updated: Jun 16, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Area of Science:

Endocrinology
Metabolic Diseases
Pharmacology

Background:

Thiazolidinediones are known to reduce hepatic steatosis and increase HDL cholesterol.
Previous studies in mice showed a link between reduced hepatic triglycerides, decreased CETP mass, and increased HDL.
Type 2 diabetes is often associated with dyslipidemia and hepatic steatosis.

Purpose of the Study:

To investigate the effect of pioglitazone on CETP mass in patients with type 2 diabetes.
To determine if pioglitazone's effects on hepatic triglyceride content and HDL cholesterol are associated with changes in CETP mass.

Main Methods:

A randomized controlled trial involving 78 men with type 2 diabetes.
Participants received pioglitazone or metformin alongside glimepiride and placebo.
Measurements included hepatic triglyceride content (proton magnetic resonance spectroscopy), plasma CETP mass, and HDL cholesterol levels after 24 weeks.

Main Results:

Pioglitazone significantly decreased hepatic triglyceride content.
Pioglitazone treatment led to a significant reduction in plasma CETP mass.
Plasma HDL cholesterol levels were significantly increased in the pioglitazone group.
Metformin did not show significant changes in these parameters.

Conclusions:

Pioglitazone reduces hepatic triglyceride content in type 2 diabetes patients.
The reduction in liver fat by pioglitazone is accompanied by decreased plasma CETP mass.
These findings in humans align with and confirm previous observations in animal models.